Europe has approved two drugs for preventing COVID-19 infection: a monoclonal antibody and a self-amplifying mRNA vaccine.

"A slow start for self-amplifying mRNA vaccines" was originally created and published by Pharmaceutical Technology, a ...

"The 12-month results from the ARCT-154 study continue to establish the durability of immune response from this self-amplifying mRNA vaccine and reinforce the ability of this vaccine to provide ...

Conventional RNA vaccines ... into a cell first self-amplifies, resulting in very high mRNA copy numbers, thereby achieving superior gene expression and an amplified protein response with a ...

a new type of mRNA vaccine that uses a self-amplifying RNA (saRNA) technology called “replicon," manufactured by Meiji Seika Pharma Co. Even if people make decisions about vaccinations in ...

The vaccine is called “self-amplifying” because it replicates within the body. At clinical trials conducted in Japan, some patients felt pain in the injected parts of their bodies. Other ...

Therefore, mRNA vaccine design, formulation, and delivery will need to be further improved to compete in this area; and self-amplifying RNAs (saRNA) may become a preferred platform, due to ...

KING OF PRUSSIA, PA — Japan’s Ministry of Health, Labor and Welfare recently granted approval for CSL and Arcturus ...

Associate Director, Vaccine Discovery, Wei Shen, Ph.D., will present a poster entitled, “A UNITE ®-based self-amplifying RNA vaccine advances anti-tumor immunity in a murine triple-negative ...

Prioritizing disease prevention naturally requires implementing effective immunization campaigns while also fostering an ...

mRNA vaccines are a novel type of vaccine that use messenger RNA (mRNA) to induce an immune response against a specific pathogen. Unlike traditional vaccines that use weakened or inactivated viruses ...